Pay-for-delay cannot be per se violation, says Third Circuit

The US Court of Appeals for the Third Circuit has ruled that pharmacies’ antitrust claims against Pfizer and Ranbaxy were correctly dismissed, due to the plaintiffs’ insistence that an allegedly anticompetitive reverse payment inherently violated California antitrust law.

Unlock unlimited access to all Global Competition Review content